Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term GROWTH-FACTOR. Found 8 abstracts

Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology. 2009 Jul;20(7):1242-8.   PMCID: PMC2699385
Smith SD, Jaffer ZM, Chernoff J, Ridley AJ. PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics. Journal of cell science. 2008 Nov;121(22):3729-36.
Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang TQ, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F, Herlyn D. Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunology Immunotherapy. 2007 Mar;56(3):359-70.
Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, Bassi DE. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cellular Oncology. 2007 Jan;29(4):289-99.
von Mehren M. Beyond imatinib: Second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clinical Colorectal Cancer. 2006 Nov;6:S30-S34.
Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Research. 2003 May;63(9):2172-8.
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase Akt-dependent pathway. Journal of Biological Chemistry. 1998 Nov;273(45):29864-72.
Skorski T, Bellacosa A, NieborowskaSkorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO Journal. 1997 Oct;16(20):6151-61.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term GROWTH-FACTOR

GROWTH-FACTOR SIGNAL-TRANSDUCTION CHRONIC MYELOID-LEUKEMIA PROTEIN-KINASE GENE-EXPRESSION PROTEINS RANDOMIZED-TRIAL PAXILLIN PHOSPHORYLATION PATIENTS PTS 2-STAGE DESIGNS chemotaxis ADAPTER HUMAN BREAST-CANCER CHRONIC MYELOGENOUS LEUKEMIA KIT mutation TYROSINE KINASE INHIBITOR PAK1 INHIBITION FIBROBLAST INTERACTIONS RAC TYPE-1 MATRIX-METALLOPROTEINASE sunitinib CANCER PATIENTS CELL-MIGRATION PHOSPHATIDYLINOSITOL 3-KINASE tumor immunity AMG 706 activation MESSENGER-RNA C-AKT HERBIMYCIN-A Akt BCR-ABL P21-ACTIVATED KINASE FACTOR LEF-1 BETA-PIX ADVANCED GASTRIC-CANCER docetaxel PI-3k chemotherapy AMN107 BONE-SARCOMA-GROUP EPITHELIAL-CELL LINE TYROSINE KINASE DNA TOPOISOMERASE-I TUMOR PROGRESSION MESYLATE IM RAD001 SH2 DOMAIN Cell adhesion 2-Cell migration-Macrophages-Rho GTPases GENE-TRANSFER TRANSCRIPTION FACTOR SNAIL ACTIVATION SUBSTRATE-SPECIFICITY metalloprotemases proprotein convertases-survival-ovarian cancer-tumor progression BCR HEPATOCELLULAR-CARCINOMA chemokines leukemogenesis PROPROTEIN CONVERTASES PLUS CISPLATIN CARCINOMA ERK1 PAK1 ADVANCED SOLID TUMORS ADVANCED ESOPHAGOGASTRIC CANCER ENDOPROTEASE IN-VITRO IN-VIVO ACQUIRED-RESISTANCE C-MYC E-CADHERIN TUMORIGENICITY irinotecan GASTROESOPHAGEAL ADENOCARCINOMA EXPRESSION MACROPHAGE BETA-CATENIN TRANSLATION INITIATION INDEPENDENCE esophageal cancer apoptosis TUMOR-GROWTH CELLS bevacizumab DENDRITIC CELLS INITIATION-FACTOR 4E CTL ABL COLLAGEN MATRIX RECEPTOR BCR-ABL ONCOGENE PANCREATIC-CANCER CELLS ADJUVANT CHEMOTHERAPY CXC-CHEMOKINE EORTC-SOFT-TISSUE
Last updated on Monday, May 04, 2020